

Decision Point: GF/B39/EDP20: Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period

The Board:

1. Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SCo4/DPo2;
2. Approves the additional incremental funding recommended for certain UQD of the following country disease component: (i) Rwanda malaria, as listed in Table 2 of GF/B39/ER16, based on available funding approved by the Audit and Finance Committee;
3. Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

Table 2: Secretariat’s Funding Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period

N	Applicant	Disease Component	Grant Name	Additional Funding Source	Currency	Previously Approved Program Budget	Recommended Additional Funding	Revised Program Budget	Strategic Priority Areas For Investments
1	Rwanda	Malaria	RWA-M-MOH	Portfolio Optimization	USD	41,460,255	13,626,690	55,086,945	These funds will be used to cover the gap in Indoor Residual Spraying (IRS).